As a consequence, disrupting metabolic control mechanisms that maintain the balance of metabolite flux between glycolysis and PPP should selectively impair the survival of p53 deficient cancer cells and could be a strategy for therapeutic intervention. This evidence concerns the gene TP53 and cancer.